Aarti Drugs Limited: Navigating Headwinds with Strategic Growth and Operational Scale-up

Aarti Drugs Limited, a prominent player in the Indian pharmaceutical sector, recently announced its financial results for the third quarter and nine months ended December 31, 2025 (Q3 & 9M FY26). The company reported a steady performance, marked by healthy traction in the domestic market and strong growth in its export formulations segment. For Q3 FY26, total revenue stood at 602.9 crore, reflecting an 8% year-on-year growth. However, EBITDA saw a 10% year-on-year contraction to 56.3 crore, with margins at 9.3%. Despite this, Profit After Tax (PAT) surged by 58% year-on-year to 40.5 crore, translating to a PAT margin of 6.7%. For the nine-month period, revenue grew by 8% to 1,846.6 crore, and EBITDA increased by 9% to 215.0 crore, with an EBITDA margin of 11.6%.

The management acknowledged that several factors weighed on the quarter's performance, including lower utilization levels, weaker antibiotic demand, delays in shipments from China, and a one-time voluntary shutdown for refurbishment at one of its plants. Additionally, new greenfield facilities operated below optimal utilization during their initial ramp-up phase. The consumption of higher-cost inventory from the previous year also impacted gross profitability. However, the company noted that January sales have shown encouraging momentum, indicating a positive trend for the coming quarters.

Segmental Performance and API Focus

The API segment continues to be the cornerstone of Aarti Drugs' business, contributing 75.5% of the total revenue in Q3 FY26, amounting to 455.2 crore. Within the API segment, Anti-biotic products led with 35.1% of API revenue (159.9 crore), followed by Anti-protozoal at 19.8% (90.1 crore), Anti-diabetic at 16.6% (75.6 crore), Anti-inflammatory at 12.9% (58.7 crore), and Anti-fungal at 12.2% (55.5 crore). The Formulation segment demonstrated encouraging traction, especially in export markets, contributing 12.7% of total revenue (76.6 crore) in Q3 FY26, marking a 58% year-on-year growth. Speciality Chemicals accounted for 8.5% (51.2 crore), and Intermediates & Others contributed 3.3% (19.9 crore).

This diversified product portfolio and segment mix have been instrumental in navigating category-specific demand fluctuations, supporting overall business stability. The increasing contribution from formulations, particularly with a higher share of exports, aligns with the company's strategy of moving towards higher-value offerings and improving overall business quality.

Strategic Initiatives and Future Outlook

Aarti Drugs is actively pursuing several strategic initiatives to drive future growth and improve operational efficiency. The state-of-the-art backward integration plant in Sayakha for methyl amines, operationalized in September 2025, achieved nearly 30% capacity utilization in its first quarter. The company expects to ramp this up to 50% by March or April 2026 and further to 80-90% within 12 months. This facility is crucial for fulfilling 10-15% of captive Metformin requirements initially, with a target of 100% self-reliance within the next 6-8 months.

The Salicylic Acid plant in Tarapur has reached a significant milestone, scaling to above 300 tonnes per month. The downstream Salicylates line is currently under implementation, which is expected to transform this segment into a primary value driver. The company aims to scale the Salicylic Acid plant to 1,000 tonnes per month within 12 months. On the regulatory front, certification and approval processes are progressing, including preparations for European approvals, with EU GMP received for both the general Talvin capsule and oncology facilities in Baddi.

Management anticipates an inflection point with stabilizing realizations and improving volume momentum. They project a 12-15% volume growth in FY27, primarily driven by new greenfield projects. The target for ideal steady-state EBITDA margins is 14-15%, with an immediate goal of 12-13%. The company remains focused on operational efficiency, margin improvement, and capacity ramp-up, while maintaining compliance with regulatory standards and capital discipline.

Concluding Thoughts

Aarti Drugs Limited's Q3 FY26 performance reflects a period of strategic transition and operational adjustments. Despite facing temporary headwinds such as higher-cost inventory and initial ramp-up challenges for new facilities, the company has demonstrated resilience through its diversified portfolio and strong volume growth in key segments. The successful operationalization and planned scale-up of the Sayakha and Salicylic Acid plants, coupled with expansion into regulated markets and the commercialization of oncology formulations, position Aarti Drugs for a new phase of growth. The management's clear focus on backward integration, margin improvement, and disciplined capital allocation underscores its commitment to sustainable long-term value creation, instilling confidence in its future trajectory.